Low‑Dose Aspirin for Primary Prevention in Adults with Intermediate ASCVD Risk

Risk–Benefit Balance

In individuals with a 10‑year ASCVD risk > 1 % (e.g., ~12 % risk), the estimated number of cardiovascular events prevented by low‑dose aspirin is roughly equal to the number of major bleeding episodes induced, resulting in a near‑neutral net clinical benefit. (Evidence from observational cohorts) 1
Real‑world data show an absolute increase of about 5 major bleeding events per 1,000 patients per year, most commonly gastrointestinal bleeding. (Observational data) 2
Treating 100 patients with aspirin for 5–10 years is expected to prevent ≈ 1 cardiovascular event while causing ≈ 1 major bleeding event, highlighting the near‑equal trade‑off. (Modeling based on trial data) 1

ASCEND trial (15 480 participants with diabetes) – aspirin reduced cardiovascular events by 12 % (relative risk reduction) but increased major bleeding by 29 %, predominantly gastrointestinal. (Randomized controlled trial, high‑quality evidence) 3
ARRIVE and ASPREE trials in non‑diabetic populations found no significant benefit on primary cardiovascular endpoints and reported higher bleeding rates with aspirin. (Randomized controlled trials, moderate‑quality evidence) 1
The modest 12 % reduction in vascular events with aspirin is driven mainly by fewer non‑fatal myocardial infarctions; there is little effect on cardiovascular mortality (relative risk ≈ 0.95). (Meta‑analysis of RCTs) 4

Contraindications – do not use aspirin when any of the following are present:
- Age > 70 years
- History of gastrointestinal ulcer or recent bleeding
- Anemia or chronic kidney disease
- (These factors were identified in the ADA guideline review) (Guideline recommendation, moderate evidence) 4
Favorable risk profile – aspirin may be considered if:
- Patient has diabetes plus at least one additional major ASCVD risk factor (e.g., hypertension, dyslipidemia, smoking, family history of premature ASCVD, or chronic kidney disease/albuminuria) (Guideline recommendation, moderate evidence) 5
- Overall bleeding risk is low (absence of the contraindications above and no concurrent anticoagulant/NSAID use) (Guideline recommendation, moderate evidence) 4
- Patient expresses willingness to adhere to daily therapy after shared decision‑making (Guideline recommendation, low‑moderate evidence) 6

Recommended dosing range is 75–162 mg daily; the 81‑mg tablet is the most commonly used formulation in the United States. (Guideline dosing recommendation) 2
The ADAPTABLE trial showed no difference in cardiovascular outcomes or bleeding between 81 mg and 325 mg daily, supporting the use of the lower dose. (Randomized controlled trial, moderate evidence) 6
Non‑enteric‑coated aspirin formulations may be preferred when a faster onset of action is desired. (Pharmacologic recommendation) 7

The American Diabetes Association (ADA) 2019‑2025 guidelines state that aspirin “may be considered” for primary prevention but is “generally not recommended” even in patients with elevated ASCVD risk. (Guideline recommendation, Grade C/D) 4
Before initiating aspirin, ensure optimal statin therapy, blood pressure control, smoking cessation, and lifestyle modification, as these interventions have stronger evidence for ASCVD risk reduction. (Guideline recommendation, high evidence for statins) 4
Reassess bleeding risk regularly; discontinue aspirin if the patient ages beyond 70 years or develops new bleeding risk factors. (Guideline recommendation, moderate evidence) 5
Emphasize that aspirin’s primary benefit is reduction of non‑fatal myocardial infarction, not mortality reduction. (Guideline recommendation, moderate evidence) 1

The American Diabetes Association recommends aspirin for patients ≥50 years with diabetes plus at least one additional major risk factor, but this patient lacks diabetes entirely 8, 9
The American College of Cardiology and American Heart Association suggest using the ACC/AHA Pooled Cohort Equations to calculate 10-year ASCVD risk, which is essential for determining aspirin eligibility 10

A 10-year ASCVD risk of ≥10% may justify aspirin consideration, but this would require shared decision-making emphasizing that bleeding risks approximately equal cardiovascular benefits 10
The USPSTF gives a Grade D recommendation (harm outweighs benefit) against initiating aspirin in adults 60 years or older, and even for ages 40-59, only those with ≥10% 10-year ASCVD risk might benefit 10

Aspirin increases the risk of major gastrointestinal bleeding by 60% (relative risk 1.6), occurring in 2-4 per 1,000 middle-aged adults over 5 years 9, 10
For non-diabetic patients, the evidence for aspirin therapy is weaker, and aspirin is explicitly not recommended for those at low ASCVD risk 10

Statin therapy is recommended if the calculated ASCVD risk warrants it (generally ≥7.5% 10-year risk), as statins have stronger evidence for cardiovascular risk reduction than aspirin 10
Blood pressure optimization to <130/80 mmHg, lifestyle modifications (smoking cessation, weight management, regular physical activity), and annual cardiovascular risk reassessment are essential for primary prevention 10